The stock of MaxCyte Inc (MXCT) has seen a -0.58% decrease in the past week, with a -10.65% drop in the past month, and a -16.91% decrease in the past quarter. The volatility ratio for the week is 7.44%, and the volatility levels for the past 30 days are at 6.01% for MXCT.. The simple moving average for the past 20 days is -5.86% for MXCT’s stock, with a -18.41% simple moving average for the past 200 days.
Is It Worth Investing in MaxCyte Inc (NASDAQ: MXCT) Right Now?
Analysts have differing opinions on the stock, with 8 analysts rating it as a “buy,” 4 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for MXCT is 97.32M, and currently, short sellers hold a 3.33% ratio of that floaft. The average trading volume of MXCT on November 15, 2024 was 371.69K shares.
MXCT) stock’s latest price update
The stock price of MaxCyte Inc (NASDAQ: MXCT) has dropped by -3.10 compared to previous close of 3.55. Despite this, the company has seen a fall of -0.58% in its stock price over the last five trading days. globenewswire.com reported 2024-11-13 that Since 1999, MaxCyte’s non-viral cell engineering innovations have helped launch pioneering cell and gene therapy projects Since 1999, MaxCyte’s non-viral cell engineering innovations have helped launch pioneering cell and gene therapy projects
Analysts’ Opinion of MXCT
Many brokerage firms have already submitted their reports for MXCT stocks, with Craig Hallum repeating the rating for MXCT by listing it as a “Buy.” The predicted price for MXCT in the upcoming period, according to Craig Hallum is $7 based on the research report published on November 29, 2023 of the previous year 2023.
MXCT Trading at -9.28% from the 50-Day Moving Average
After a stumble in the market that brought MXCT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -37.96% of loss for the given period.
Volatility was left at 6.01%, however, over the last 30 days, the volatility rate increased by 7.44%, as shares sank -9.23% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -13.13% lower at present.
During the last 5 trading sessions, MXCT fell by -0.58%, which changed the moving average for the period of 200-days by -32.42% in comparison to the 20-day moving average, which settled at $3.65. In addition, MaxCyte Inc saw -26.81% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at MXCT starting from Erck Stanley C, who sale 47,689 shares at the price of $3.72 back on Nov 01 ’24. After this action, Erck Stanley C now owns 269,118 shares of MaxCyte Inc, valued at $177,403 using the latest closing price.
Johnston John Joseph, the Director of MaxCyte Inc, sale 3,000 shares at $3.72 during a trade that took place back on Oct 28 ’24, which means that Johnston John Joseph is holding 141,950 shares at $11,166 based on the most recent closing price.
Stock Fundamentals for MXCT
Current profitability levels for the company are sitting at:
- -1.02 for the present operating margin
- 0.79 for the gross margin
The net margin for MaxCyte Inc stands at -0.78. The total capital return value is set at -0.2. Equity return is now at value -16.00, with -13.87 for asset returns.
Currently, EBITDA for the company is -44.13 million with net debt to EBITDA at 0.44. When we switch over and look at the enterprise to sales, we see a ratio of 7.55. The receivables turnover for the company is 10.0for trailing twelve months and the total asset turnover is 0.18. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.81.
Conclusion
In a nutshell, MaxCyte Inc (MXCT) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
